ecancermedicalscience

Research

Haemoglobin levels may predict toxicities in patients on pelvic chemoradiation for carcinoma of the cervix—experience of a regional cancer centre

19 May 2014
Aparna Gangopadhyay, Joydeep Das, Partha Nath, Jaydip Biswas

Background: Haemoglobin levels and tissue oxygenation influence tumour outcome in carcinoma cervix radiotherapy. The clinical impact of haemoglobin levels on acute normal tissue toxicity during radiation and interaction with chemotherapy in carcinoma of the cervix is underexplored. This paper aims to explore this issue.

Methods: Treatment toxicity among 227 patients with squamous cell carcinoma of the cervix stages II B–IV A, receiving pelvic radiotherapy or chemoradiation at our institute, were studied prospectively. The baseline and weekly haemoglobin levels during treatment were recorded. Acute toxicities were recorded using Radiation Therapy Oncology Group (RTOG) acute toxicity and Common Terminology Criteria for Adverse Events (CTCAE) criteria, version 4. For the analysis, patients were divided into two groups, depending on nadir haemoglobin levels. A cut-off value for anaemia was selected at 12 gm/dL. Toxicity was compared between anaemic and non-anaemic groups.

Results: Patients on chemoradiation and having haemoglobin levels >12 gm/dL suffered significantly higher dermatitis (two-tailed p value = 0.0288) and vaginal mucositis (two-tailed p value = 0.0187) of at least RTOG acute toxicity grade 2, compared with the anaemic group. In contrast patients receiving radiotherapy alone did not experience any significantly greater mucocutaneous toxicity if haemoglobin was >12 gm/dL. Anaemia had significantly greater impact on malaise and neutropenia (two-tailed p value <0.0001) of CTCAE grade 1 and above among chemoradiation patients, as opposed to those receiving radiotherapy alone (two-tailed p values = 0.0012 for neutropenia and 0.0422 for malaise).

Conclusion: Haemoglobin values >12 gm/dL significantly worsen acute mucocutaneous toxicity in locally advanced cervical cancer patients receiving chemoradiation. Similar effects are not observed in the absence of chemotherapy.

Related Articles

Joseph Weygand, Yao Hao, Munir Awol, Adedayo O Joseph, Solomon Kibudde, Abba Malloum, Twalib A Ngoma, Samuel O Adeneye, Kavuma Awusi, Jumaa D Kisukari, Thokozani Mkhize, Maureen Bilinga Tendwa, Victoria Ainsworth, Azeezat Ajose, William Swanson, Stephen Avery, Rohini Bhatia, Frank Chinegwundoh, Curtiland Deville, Mohammed Saiful Huq, Heng Li, Joerg Lehmann, Christopher F Njeh, Krishni Wijesooriya, Wilfred Ngwa, Katy Graef, Janine Simons, Onyinye Balogun, Luca Incrocci
Arunah Chandran, Ishu Kataria, Kunal Oswal, Rita Isaac, Meritxell Mallafré-Larrosa, Sathishrajaa Palaniraja, Rajaraman Swaminathan, Rohit Rebello, Nandimandalam Venkata Vani, Bindhya Vijayan, Moni Kuriakose, Arnie Purushotham, Rengaswamy Sankaranarayanan, Jerard Selvam, Richard Sullivan, Partha Basu
Sarah O John-Olabode, Ifeoma C Udenze, Adebola A Adejimi, Obiefuna Ajie, Kehinde S Okunade
José Richard Tenazoa-Villalobos, Edgar Fermín Yan-Quiroz, Augusto Ordoñez-Chinguel, Sofia Leonor Prado-Cucho, Adesman Isac Miranda-Narro, Vladimir Villoslada-Terrones